Abbott (NYSE:ABT) touted data from a 5,400 patient study evaluating daily opioid use following spinal cord stimulation therapy in patients with chronic pain. The researchers found that average daily opioid use declined or remained steady for patients with a spinal cord stimulation system compared to patient use of opioids prior to the implant.
Patients who had the spinal cord stim implant removed experienced greater opioid use over time, the company reported. In a spinal cord stimulation system, a device similar to a pacemaker is implanted in the patient’s spinal cord and delivers low levels of electrical energy to nerve fibers. The energy disrupts pain signals as they travel to the brain, reducing the sensation of pain.
Get the full story at our sister site, Drug Delivery Business News.
The post Abbott touts study showing SCS helps curb opioid use in chronic pain patients appeared first on MassDevice.
from MassDevice http://ift.tt/2jQVkOn
Cap comentari:
Publica un comentari a l'entrada